Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain-binding protein 4 (SH3BP4) is an adaptor protein involved in the control of clathrin-mediated endocytosis and the trafficking of the transferrin receptor, containing motifs for interaction with endocytic and signaling proteins, including an SH3 domain, NPF repeats (EH domain-binding sites), and a death domain. SH3BP4 acts as a negative regulator of mTORC1 signaling by binding inactive Rag GTPase complexes, thereby impeding mTORC1 activation in response to amino acids. This regulatory function implicates SH3BP4 as a potential tumor suppressor, as deletions of the SH3BP4 locus are seen in several cancer types. SH3BP4 is highly conserved among vertebrates and is linked to both endosomal trafficking and cell signaling networks[1][2][3][4].
Inhibition of amino acid-induced activation of mTORC1 by binding inactive Rag GTPase complexes[2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3 domain-binding protein 4 (SH3BP4).